Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection

Table 1 Characteristics of patients

Patient No.	Age (yr)	Gender	Diagnosis	Previous IFN therapy	Other medications
1	73	F	LC	Not eligible	Glycyrrhizin
2	78	F	LC	Not eligible	Glycyrrhizin
3	49	M	LC	Not eligible	Glycyrrhizin
4	72	M	LC + HCC	Not eligible	Glycyrrhizin
5	66	M	LC + HCC	Not eligible	Glycyrrhizin
6	70	M	LC	Not eligible	None
7	70	F	CHC	Not eligible	Glycyrrhizin
8	86	F	CHC	Not eligible	Glycyrrhizin
9	55	M	CHC	Intolerant	None
10	69	M	CHC	Non-responder	Glycyrrhizin
11	71	M	CHC	Non-responder	Glycyrrhizin
12	68	F	CHC	Non-responder	Glycyrrhizin
13	61	F	CHC	Non-responder	Glycyrrhizin
14	62	F	CHC	Non-responder	None
15	42	F	CHC	Non-responder	None

M: Male; F: Female; LC: Liver cirrhosis; CHC: Chronic hepatitis C; HCC: Hepatocellular carcinoma; IFN: Interferon.